A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Pandit, Vinay
- Recent Updates on Psoriasis: A Review
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 1 (2022), Pagination: 76 - 83Abstract
In the past 15 years, breakthroughs in the understanding towards the pathogenesis of psoriasis have been translated into highly and targeted effective therapies which provides fundamental insights into the pathogenesis of chronic inflammatory diseases. In this article we understand the mechanisms involved in the initiation and development of psoriasis, as well as the therapeutic options that arises from the dissection of the inflammatory psoriatic pathways. The whole discussion begins by addressing the inflammatory pathways and key cell types which initiating and perpetuating the psoriatic inflammation. Also, we discuss the role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis. So, we the purpose of our study is to understand psoriasis comprehensively, and this review is well-established to explain the therapies, and other novel targeted drugs that are mostly used in the effective treatment of psoriasis.
Keywords
Psoriasis, Types, Pathogenesis, Epidemiology, PharmacotherapyReferences
- Mabuchi T, Chang TW, Quinter S and Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. Journal of Dermatological Science. 2012;65(1): 4-11
- Tsuruta D. NF-κB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Patents on Inflammation and Allergy Drug Discovery. 2009; 3(1): 40-8.
- Krueger JG and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Annals of the Rheumatic Diseases 2005; 64(2): 30-6.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian Journal of Pharmaceutical Research. 2021;11(1):43-5.
- Nograles KE and Krueger JG. Anti-cytokine therapies for psoriasis. Experimental Cell Research. 2011; 317(9): 1293-300.
- Galimova ES, Akhmetova VL and Khusnutdinova EK. Molecular genetic basis of susceptibility to psoriasis. Russian Journal of Genetics. 2008; 44(5): 513.
- Campalani E and Barker JN. The clinical genetics of psoriasis. Current Genomics. 2005; 6(1): 51-60.
- A Kumar, S Jindal, MS Ashawat, V Pandit, V Priya. Psoriasis and Its Treatment: A Review.
- Vani PB, Kumar PR. A Comparative Review on Conventional and Traditional medicine in the Treatment of Psoriasis. Research Journal of Pharmacy and Technology. 2020;13(11):5642-6.
- Lebwohl M, Menter A, Koo J and Feldman SR. Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2004; 50(3): 416-30.
- Armstrong AW, Schupp C, Wu J and Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS one. 2012; 7(12): e52935.
- Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A and Turner ML. Quantifying the harmful effect of psoriasis on health-related quality of life. Journal of the American Academy of Dermatology 2002; 47(4): 512-8.
- Kimball AB, Gieler U, Linder D, Sampogna F and Warren RB: 33. Psoriasis: is the impairment to a patient’s life cumulative? Journal of the European Academy of Dermatology and Venereology. 2010; 24(9): 989-04. 34.
- Azfar RS, Seminara NM, Shin DB, Troxel AB and Margolis DJ. Increased risk of diabetes mellitus and the likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Archives of Dermatology. 2012; 148(9): 995-00. 35.
- Iriventi P, Gupta NV. Formulation and Evaluation of herbal cream for treating psoriasis. Research Journal of Pharmacy and Technology. 2021;14(1):167-70.
- Gisondi P and Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermo- Sifiliograficas. 2009; 100: 14-21.
- Paller AS, Mercy K, Kwasny MJ, Choon SE and Cordoro KM. 37. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatology. 2013; 149(2): 166-76.
- Parisi R, Symmons DP, Griffiths CE and Ashcroft DM. Global 38. epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013; 133: 377- 85. 286-92.
- Pradhan M, Alexander A. Development and Validation of a 39. Robust RP-HPLC Method for Analysis of Calcipotriol in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2019;12(2):579-83.
- Bedi TR. Clinical profile of psoriasis in North India. Indian Journal of Dermatology, Venereology and Leprology. 1995; 61(4): 202.
- Kaur I, Handa S and Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. The Journal of Dermatology. 1997; 24(4): 230-4.
- Gillard SE and Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. International Journal of Clinical Practice. 2005; 59(11): 1260-7.
- Rawat Singh M, Pradhan K and Singh D. Lipid matrix systems with emphasis on lipid microspheres: potent carriers for transcutaneous delivery of bioactives. Current Drug Delivery. 2012; 9(3): 243-54.
- Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. Journal of Controlled Release. 2001; 73(2- 3): 137-72.
- Kaplan FO, Daniel H and Barker J: Mechanisms of Disease: Psoriasis. Nestle In: New England Journal of Medicine. 2009; 361(5): 496-09.
- Christophers E, Segaert S, Milligan G, Molta CT and Boggs R: Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross- sectional observational study. Journal of Dermatological Treatment. 2013; 24(3): 193-8.
- Chaurasia V, Pal S. Skin diseases prediction: binary classification machine learning and multi model ensemble techniques. Research Journal of Pharmacy and Technology. 2019;12(8):3829-32.
- Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D and Michalak-Stoma A. Cytokines and anticytokines in psoriasis. Clinica Chimica Acta. 2008; 394(1-2): 7-21.
- Raychaudhuri SP and Gross J: A comparative study of pediatric- onset psoriasis with adult-onset psoriasis. Pediatric Dermatology. 2000; 17(3): 174-8.
- Yadav K, Singh D, Singh MR. Development and characterization of corticosteroid loaded lipid carrier system for psoriasis. Research Journal of Pharmacy and Technology. 2021;14(2):966-70.
- D'souza JI, More HN. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Research Journal of Pharmacy and Technology. 2008; 1(4):502-6.
- Kavitha S. Pharmacognostical Evaluation and Standardisation of Ayurvedic Formulation Patoladi Kwatha Churna for Psoriasis. Research Journal of Pharmacy and Technology. 2020; 13(3): 1171-4.
- Wozel G: Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clinics in Dermatology. 2008; 26(5): 448- 59.
- Mahajan Tejasavi, Singh Navdeep, Goyal Kamya, Pandit Vinay, Ashawat M.S., Jindal Shammy. World dendrimer as a potential drug delivery system: a review. Journal of Pharmacy and Pharmaceutical Sciences. 2021; 10 (4): 1818-1827
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Andrographolide loaded topical nanocarriers for management of psoriasis: a safe and effective approach. Plant Archives. 2021; 21(1):1899-902.
- Krishnamurthy K, Walker A, Gropper CA and Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. Journal of Drugs in Dermatology. 2010; 9(3): 241-50.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Preparation and in vitro evaluation of Tacrolimus loaded liposomal vesicles by two methods: A comparative study. Journal of Research in Pharmacy. 2021, 25(1): 34-41.
- Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2020; 10(4):286-92.
- Nandgude TD, Hasabe PS, Kolsure AK. Clinical Features and Treatment of Rheumatoid Arthritis: A Review. Research Journal of Pharmacy and Technology. 2018;11(12):5701-6.
- Kumar A, Goyal K, Pandit V , Ashawat MS, Jindal S. Simultaneous estimation of Halobetasol propionate and Tazarotene in pure and dosage form by using UV-Visible Spectrophotometric method. Research Journal of Pharmacy and Technology. 2020; 13(10): 4711-4.
- Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Medical Hypotheses. 2020; 142:109838.
- Sondhi S, Singh N, Goyal K, Jindal S. A Laconic Review on Extraction, Biological Activities of Herbal Formulations of Berberine: A Traditional Drug. Journal of Drug Delivery and Therapeutics. 2020;10(5):345-57.
- Singh N, Goyal K, Sondhi S, Jindal S. Traditional and medicinal use of Barbaloin: potential for the management of various diseases. Journal of Applied Pharmaceutical Research. 2020; 8(3):21-30.
- Mrowietz U, Kragballe K, Reich K, Spuls P and Griffiths CE: Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research. 2011; 303(1): 1-0.
- Singh N, Goyal K, Sondhi S, Jindal S. Development and Characterization of Barbaloin Gel for the Safe and Effective Treatment of Psoriasis. Journal of Drug Delivery and Therapeutics. 2020; 10(5):188-97.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian Journal of Pharmaceutical Research. 2021;11(1):43-5.
- Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of Psoriasis: A Laconic Review. Asian Journal of Research in Pharmaceutical Sciences. 2021;11(1):51-7.
- Sondhi S, Singh N, Goyal K, Jindal S. Development of Topical Herbal Gel of Berberine Hydrochloride for the Treatment of Psoriasis. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021;13(1):12-8.
- Sharma A, Anghore D, Awasthi R, Kosey S, Jindal S, Gupta N, Raj D, Sood R. A Review on Current Carbon Nanomaterials and Other Nanoparticles Technology and Their Applications in Biomedicine. World Journal Pharmacy and Pharmaceutical Science. 2015;4(12):1088-113.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Isolation, characterization and evaluation of anti-proliferative properties of andrographolide isolated from Andrographis paniculata on cultured HaCaT cells. Herba Polonica. 2021; 67(1): 35-45.
- Rheumatoid Arthritis, a Laconic Review to Understand Their Basic Concept and Management Process
Authors
1 Research Scholar, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
2 Assistant Professor, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
3 Head of Department, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
4 Director cum Principal, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh 176031, IN
5 Assistant Professor, Laureate Institute of Pharmacy, Jawalmukhi - 176031, Himachal Pradesh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 4 (2022), Pagination: 312 - 322Abstract
Rheumatoid arthritis is a chronic inflammatory illness characterized by joint stiffness, bone and cartilage destruction, and swelling above the joints. The condition is linked to chemicals found within the major histocompatibility complex, also as T-cells that are hooked in to them. The condition is more severe in women than in men, also as within the elderly population. The effects of gender on the clinical course of the disease are studied, but the results are mixed. The factor like genetic, environmental, smoking, and age of a person were trigger’s the rheumatoid arthritis. The other clinical complications were observed in patients with rheumatoid arthritis which includes depression, infection, malignancy, cardiovascular disorder, pulmonary disease etc. According to research, RA risk might be impacted by a genetic predisposition, environmental factors, or a combination of both. Immune cells such as lymphocytes, neutrophils, and macrophages have long been thought to have a role in the development of RA involved in pathological mechanism. Rheumatoid arthritis have been diagnosed by imaging with colour doppler sonography or gadolinium-enhanced magnetic resonance imaging can detect the presence of osynovitis, and serologic testing for auto-antibodies and APRs was required to diagnose rheumatoid arthritis. To cure and prevent the patients form rheumatoid arthritis it is very necessary to take suitable treatment. So, in present work we also highlighted the available drugs used for the treatment of RA. The first line therapy agents include Non-steroidalantiinflammatory drugs, and corticosteroids. The second line agents used in RA are Disease modifying Antirheumatic drugs (DMARDs). The patients having age more than 60 years also need surgery to cure rheumatoid arthritis. To decrease the side effects from some potent agents include methotrexate the vitamin D, folic acid, and dietary supplements were used with treatment. So, this review article helps the researcher’s to understand the basic overview of rheumatoid arthritis, causes, other disease development, and management process with regards to available FDA approved therapeutics, and published patents.
Keywords
Rheumatoid arthritis, Etiology, Pathophysiology, Diagnosis, TreatmentReferences
- Aloke C, Ibiam UA, Orji OU, Ugwuja EI, Ezeani NN, Aja PM, Obasi NA. Anti-arthritic potentials of ethanol and aqueous extracts of stem bark of Cleistopholis patens on complete Freund's adjuvant-induced rheumatoid arthritis in rats. Journal of Ayurveda and Integrative Medicine. 2019:9.
- 2. Girdler SJ, Ye I, Tang R, Kirschner N. Altering the natural history of rheumatoid arthritis: The role of Immunotherapy and biologics in orthopaedic care. Journal of Orthopaedics. 2020; 17:17-21.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Jayashree S, Nirekshana K, Guha G, Bhakta-Guha D. Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection. Biomedicine and Pharmacotherapy. 2018; 102:894-911.
- Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. and Research 2(1): Jan.-March 2012; Page 28-32.
- Tanaka S. Emerging anti-osteoclast therapy for rheumatoid arthritis. Journal of Orthopaedic Science. 2018;23(5):717-21.
- Wang X, Fang G, Yang Y, Pang Y. The newly discovered natural compounds against rheumatoid arthritis-an overview. Phytochemistry Letters. 2019; 34:50-8.
- Rekha Rani Nar, Ashok Kumar, S. Jeeva. Assessment and comparison of knowledge and attitude regarding pulmonary tuberculosis and compliance to Anti-Tuberculosis Treatment (A TT) of pulmonary tuberculosis patients under intensive and continuation phase of treatment at selected DOTS centers of Ambala, Haryana. Asian J. Nur. Edu. and Research 2(4): Oct-Dec. 2012; Page 190-194.
- Martins P, Fonseca JE. How to investigate: Pre-clinical rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2019;33(4):101438.
- Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology. 2017;56(8):1254-63.
- Ramachandra. Hypochondria - Historical Perspectives, Diagnosis and Management. Asian J. Nur. Edu. and Research 3(4): Oct.- Dec., 2013; Page 219-223.
- ChangK,YangSM,KimSH,HanKH,ParkSJ,ShinJI.Smokingand rheumatoid arthritis. International Journal of Molecular Sciences. 2014;15(12):22279-95.
- Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International Journal of Clinical Rheumatology. 2011;6(6):617.
- Atzeni F, Masala IF, Di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Current Opinion in Rheumatology. 2017;29(4):323-30.
- Neethu Jose. Bee Venom Therapy (BVT). Asian J. Nur. Edu. and Research 5(2): April-June 2015; Page 293-296.
- Ellman P, Ball RE. “Rheumatoid disease” with joint and pulmonary manifestations. British Medical Journal. 1948;2(4583):816.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143-54.
- Nirmala Jyothi. A Case Report on Pica: A rare pregnancy related complication. Asian J. Nur. Edu. and Research 5(1): Jan.-March 2015; Page137-139.
- Wegierska M, Dura M, Blumfield E, Żuchowski P, Waszczak M, Jeka S. Osteoporosis diagnostics in patients with rheumatoid arthritis. Reumatologia. 2016;54(1):29.
- Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45(6):669-75.
- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl_5): v3-11.
- Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology. 2015;54(5):768-75.
- Jophin Joseph. Pierre Robin Sequence / Pierre Robin malformation. Asian J. Nur. Edu. and Research. 2016; 6(2): 265-273.
- Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12(3):183-9.
- Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. BioMed Research International. 2014.
- Kekow J, Koczan D, Drynda S, Drynda A, Thiesen H. Modulation of the gene expression pattern in peripheral blood mononuclear cells by biologicals in rheumatoid arthritis. Arthritis Res Ther. 2003;5(3):1-54.
- Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity. 2012;39(3):222-8.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B. American College of Rheumatology, European League Against Rheumatism, et al: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-81.
- Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Annals of the Rheumatic Diseases. 2014;73(1):114-23.
- Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D. Distinctions between diagnostic and classification criteria?. Arthritis Care and Research. 2015;67(7):891.
- Mohd. Yaqub Khan, Poonam Gupta, Vikas Kumar Verma. A Review- Biomedical Engineering-Present and Future Prospective.Asian J. Pharm. Res. 3(4): Oct. - Dec.2013; Page 202-206.
- Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the Rheumatic Diseases. 2002;61(4):290-7.
- Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research and Therapy. 2005;7(4):1-1.
- Van der Heijde DM, van Riel PL, van Leeuwen MA. vant Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. Br J Rheumatol. 1992; 8:519-26.
- St Clair EW. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-43.
- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases. 2016;75(1):3-15.
- Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Annals of the Rheumatic Diseases. 2012;71(10):1702-5.
- Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism. 2011;63(3):573-86.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Krushna K. Zambare, Avinash B. Thalkari. Overview on Pathophysiology of Pneumonia. Asian J. Pharm. Res. 2019; 9(3):177-180.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma and Clinical Immunology. 2013;9(1):1-25.
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2010;69(6):964-75.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Silva JC, Mariz HA, Rocha LF, Oliveira PS, Dantas AT, Duarte AL, Pitta ID, Galdino SL, Pitta MG. Hydroxychloroquine decreases Th17- related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013; 68:766-71.
- Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, Koch AE. Treatment with sulfasalazine or sulfapyridine, but not 5‐aminosalicylic acid, inhibits basic fibroblast growth factor–induced endothelial cell chemotaxis. Arthritis and Rheumatism: Official Journal of the American College of Rheumatology. 1999;42(9):1927-35.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2013;6: CMAMD-S5558.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatology and Therapy. 2017;4(2):247-61.
- Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety. 2011;2(3):113-28.
- Halstead JA, Stoten S. Orthopedic Nursing: Caring for Patients with Musculoskeletal Disorders. Bridgewater: Western Schools. 2010.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Cooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, Jones JG, Maddison P, Thom JM. Benefits of exercise in rheumatoid arthritis. Journal of Aging Research.13;2011
- Zitnay JL, Li Y, Qin Z, San BH, Depalle B, Reese SP, Buehler MJ, Yu SM, Weiss JA. Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nature Communications. 2017;8(1):1-2.
- Burska AN, Roget K, Blits M, Gomez LS, Van De Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, Van Baarsen LG, Ponchel F. Gene expression analysis in RA: towards personalized medicine. The Pharmacogenomics Journal. 2014;14(2):93-106.
- Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, Kameda H, Amano K, Matsubara K, Matoba R, Takeuchi T. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Research and Therapy. 2016;18(1):1-2.
- Gonzalez-Alvaro I, Ortiz AM, Seoane IV, Garcia-Vicuna R, Martínez C, Gomáriz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Current Pharmaceutical Design. 2015;21(2):170-81.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- Cavet GL, Shen Y, Knowlton N, Centola M, inventors; Oklahoma Medical Research Foundation, Crescendo Bioscience Inc, assignee. Biomarkers and methods for measuring and monitoring inflammatory disease activity. United States Patent US 9,200,324. 2015 Dec 1.
- Stolle RJ, Beck LR, inventors; Stolle Research, Development Corp, assignee. Prevention and treatment of rheumatoid arthritis. United States Patent US 4,732,757. 1988 Mar 22.
- Nithyashree RS, Deveswaran R. A Comprehensive Review on Rheumatoid Arthritis. Journal of Pharmaceutical Research International. 2020 Jul 27:18-32.
- Spencer WP, Millsap PS. Esterified fatty acid composition - IMAGENETIX, INC. Freepatentsonline.com; 2009. [Online] Available:http://www.freepatentsonline.com /y2009/0252692.html (Accessed 17 December 2019)
- Tetracycline Compounds for the Treatment of Rheumatoid Arthritis and Related Methods of Treatment - Patent US2010190755 - PubChem. Available:https://pubchem.ncbi.nlm.nih.gov /patent/US2010190755 (Accessed: 21 December 2019)
- Google.com. WO2015177097A1 - Treatment for rheumatoid arthritis - Google Patents; 2015. [Online] Available:https://patents.google.com/paten t/WO2015177097A1/en (Accessed 17 December 2019)
- Freepatentsonline.com. FPO IP Research and Communities; 2019. [Online] Available: http://www.freepatentsonline.com/result.html?sort=relevance&srch=to p&query_txt=5908628&submit=&patents_us=o n (Accessed 17 December 2019)
- Golini JM. Cetylated fatty acid and alkali buffered creatine anti- inflammatory composition –Golin, JeffreyM. Freepatentsonline.com; 2011. [Online] Available:http://www.freepatentsonline.co m/y2011/0039928.html (Accessed 17 December 2019)
- Cohen R, Belder-Carr S, Hagerty D, Peach RJ, Becker JC, inventors; Bristol Myers Squibb Co, assignee. Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule. United States patent US 8,703,718. 2014 Apr 22.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- LingNC,WangSL,WangD,SinghS,inventors;NestecSA,assignee. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis. United States Patent US 8,519,096. 2013 Aug 27.
- Thompson P, Blumberg H, Chandrasekher YA, Novak JE, inventors; Zymogenetics Inc, assignee. Method of treating rheumatoid arthritis using anti-IL-20 antibodies. United States Patent US 8,728,469. 2014 May 20.
- Trentham DE, Weiner HL, Hafler DA, inventors; Autoimmune Inc, assignee. Method of treating rheumatoid arthritis with type II collagen. United States Patent US 5,399,347. 1995 Mar 21.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Van'tklooster GA, Namour FS, Brys RC, Van Rompaey LJ, inventors; Galapagos NV , assignee. Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof. United States Patent US 9,284,311. 2016 Mar 15.
- O'brien PM, Anderson E, Bolton GL, Ferguson DA, Jiang X, Kral Jr RM, Visnick M, inventors; Reata Pharmaceuticals Inc, assignee. Compounds Including an Anti-inflammatory Pharmacore and Methods of use. 2015 Jan 21.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Medich JR, Ruperto N, Martini A, Lovell DJ, Giannini EH, inventors; AbbVie Biotechnology Ltd, assignee. Uses and Compositions for Treatment of Juvenile Rheumatoid Arthritis. United States Patent application US 14/935,991. 2016 Sep 29.
- Huang X, Jasson M, Marks V, Radin A, Fan C, Van Hoogstraten H, Fiore S, Van Adelsberg J, Genovese M, inventors; Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc, assignee. Compositions for the treatment of rheumatoid arthritis and methods of using same. United States Patent Application US 15/034,531. 2016 Sep 29.
- Palombella VJ, Kutok JL, inventors; Infinity Pharmaceuticals Inc, assignee. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors. United States Patent Application US 13/839,912. 2014 May 1.
- Vakkalanka SK, Viswanadha S, inventors; Rhizen Pharmaceuticals SA, assignee. Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor. United States Patent US 9,737,521. 2017 Aug 22.
- Fisher E, Edwards III C, Kieft G, inventors; Amgen Inc, assignee. Nucleic acids encoding truncated soluble tumor necrosis factor. United States Patent US 7,732,587. 2010 Jun 8.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Schwaeble HW, Dudler T, Tedford CE, Parent JB, Demopulos GA, inventors; University of Leicester, Omeros Medical Systems Inc, assignee. Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation. United States Patent US 8,652,477. 2014 Feb 18.
- Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatiod arthritis: An updated overview of latest therapy and drug delivery. Journal of Pharmacopuncture. 2019;22(4):210.